| Hepatocellular Carcinoma |
1 |
1 |
| Biologic Therapy |
0 |
0.55 |
| T-Lymphocyte |
0 |
0.5 |
| Angiogenesis Inhibitors |
0 |
0.45 |
| Cancer |
0 |
0.42 |
| Immunotherapy |
0 |
0.42 |
| Nucleoside Reverse Transcriptase Inhibitors |
0 |
0.42 |
| Toxicology |
0 |
0.34 |
| Liver Disease |
0 |
0.29 |
| Liver Tumor |
0 |
0.24 |
| HIV Infection |
0 |
0.22 |
| Antigens |
0 |
0.21 |
| California |
0 |
0.21 |
| Cardiovascular disease |
0 |
0.21 |
| Chronic Hepatitis B Virus (HBV) |
0 |
0.21 |
| Hemorrhage |
0 |
0.21 |
| Humanized Monoclonal Antibody |
0 |
0.21 |
| Liver |
0 |
0.21 |
| Lymphocytes |
0 |
0.21 |
| Steroids |
0 |
0.21 |
| Tumor |
0 |
0.21 |
| Antiretroviral Therapy for HIV Infection |
0 |
0.18 |
| Hepatitis B Virus |
0 |
0.15 |
| Cardiovascular Risk Management |
0 |
0.09 |